JSJustyna Sieber

Justyna Sieber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Justyna Sieber has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Zsolt Szépfalusi

    Department of Pediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria

    5 shared publications
  • Florian Götzinger

    Department of Paediatrics and Adolescent Medicine Klinik Ottakring Vienna Austria

    3 shared publications
  • Karin Stiasny

    Center for Virology Medical University of Vienna Vienna Austria

    3 shared publications
  • Klara Schmidthaler

    Division of Paediatric Pulmonology, Allergy and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics Medical University of Vienna Vienna Austria

    3 shared publications
  • Lukas Weseslindtner

    Center for Virology Medical University of Vienna Vienna Austria

    3 shared publications
  • Sonja Kopanja

    Division of Paediatric Pulmonology, Allergy and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics Medical University of Vienna Vienna Austria

    3 shared publications

Latest Publications

  • Open Access

    Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children

    by Varsha Dwivedi, Klara Schmidthaler, Hilal Demir, Justyna Sieber, René Gaupmann, Livia Mia Gona‐Höpler, Christina Bannert, Saskia Gruber, Eleonora Dehlink, Thomas Eiwegger, et al.

    Background: Sublingual allergen immunotherapy (SLIT) is an effective treatment for immunoglobulin (Ig)E‐mediated allergies. Its success is associated with allergen‐specific (s)IgG, which blocks IgE‐mediated mechanisms. Preventive effects of SLIT in children before allergy‐symptom onset remain largely unexplored. Methods: A randomized trial was conducted between October 06, 2017 and December 15, 2022, which included house dust mite (HDM)‐sensitized preschool children (aged 3–5 years) showing no allergy symptoms. They were randomized (2:2 blocks) to HDM‐SLIT (300 index of reactivity/day, Staloral) or placebo solution for 2 years. Children receiving > 4 months of treatment were included in the analysis. Primary objective of the study was to compare the groups for change in major HDM allergen‐Der p 1‐sIgG levels from baseline to end of treatment (EOT). Secondary objectives were to compare longitudinal changes (at 4 and 12 months, and EOT) in the (i) levels of HDM‐sIgG subclasses and ‐sIgE using ImmunoCAP/‐ISAC and/or ELISA (ii) Der p‐reactivity in skin and basophils using skin prick test and basophil activation test (BAT), (iii) sensitization status defined as sIgE‐positivity in skin and/or serum, and (iv) Der p‐sIgE‐blocking activity using inhibition‐BAT. Results: Eighteen children received HDM‐SLIT (mean age = 4.26 ± 0.37 years, eight females) and 15 placebo (mean age = 4.16 ± 0.59 years, nine females). HDM‐SLIT increased Der p 1‐sIgG levels between baseline and EOT versus placebo (effect size = 3.11 [95% CL 1.36–4.82], p = 0.001). Additional changes induced by HDM‐SLIT were: increased levels of HDM‐sIgG 1 and ‐sIgG 4 , no long‐term increase in HDM‐sIgE levels, reduced Der p‐reactivity in skin and basophils ( p values ≤ 0.05), and blunted development of new sensitizations. Sera from HDM‐SLIT treated individuals displayed blocking activity on basophils ( p values ≤ 0.05). Conclusions: Preventive application of HDM‐SLIT in allergy‐prone children induces immunomodulatory effects early during treatment (elevated sIgG levels with blocking activity and reduced effector cell responses), thereby revealing potential to interfere with allergy development. Trial Registration: EudraCT#2016‐002844‐18

  • Open Access

    Preventive allergen immunotherapy with inhalant allergens in children

    by Varsha Dwivedi, Sonja Kopanja, Klara Schmidthaler, Justyna Sieber, Christina Bannert, Zsolt Szépfalusi

    The efficacy and safety of preventive allergen immunotherapy (pAIT) in children are currently under investigation. Here, we provide an overview of pAIT with respiratory allergens concerning the prevention of new sensitizations, allergic disease onset and progression as well as further immunomodulatory effects. Three databases were searched for clinical pAIT studies in children. Selected publications were reviewed for preventive outcomes according to prevention level (primary, secondary, and tertiary), allergen type, administration route, dose, and treatment duration. The primary prevention approach appears safe but showed no allergen‐specific effect on new sensitizations. Secondary prevention seems feasible and may induce regulatory T cell‐mediated immunotolerance. The number of studies at these prevention levels is limited. Tertiary prevention with grass and/or tree pollen‐based pAIT has shown efficacy in preventing disease progression from allergic rhinitis/conjunctivitis to asthma. Data on tertiary pAIT with house dust mites and other allergen types are inconclusive. Subcutaneous and sublingual routes appear similarly effective, but head‐to‐head comparative paediatric studies are scarce. Additionally, there are fewer placebo‐controlled studies. Nevertheless, immunomodulatory outcomes of pAIT are encouraging. Currently, limited but favourably suggestive evidence is available for preventing respiratory allergic diseases in children by pAIT. Primary and secondary prevention have potential and warrant further investigation through well‐designed studies.


  • Open Access

    Limited role of children in transmission of SARS‐CoV‐2 virus in households—Immunological analysis of 26 familial clusters

    by Justyna Sieber, Klara Schmidthaler, Sonja Kopanja, Lukas Weseslindtner, Karin Stiasny, Florian Götzinger, Alexandra Graf, Pavla Krotka, Jakub Hoz, Anja Schoof, et al.

    Background: The impact of children on the transmission of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) remains uncertain. This study provides an insight into distinct patterns of SARS‐CoV‐2 household transmission in case of pediatric and adult index cases as well as age‐dependent susceptibility to SARS‐CoV‐2 infection.Methods: Immune analysis, medical interviewing, and contact tracing of 26 families with confirmed SARS‐CoV‐2 infection cases have been conducted. Blood samples were analyzed serologically with the use of a SARS‐CoV‐2‐specific IgG assay and virus neutralization test (VNT). Uni‐ and multivariable linear regression and mixed effect logistic regression models were used to describe potential risk factors for higher contagiousness and susceptibility to SARS‐CoV‐2 infection.Results: SARS‐CoV‐2 infection could be confirmed in 67 of 124 family members. Fourteen children and 11 adults could be defined as index cases in their households. Forty of 82 exposed family members were defined as secondarily infected. The mean secondary attack rate in households was 0.48 and was significantly higher in households with adult than with pediatric index cases (0.85 vs 0.19; p < 0.0001). The age (grouped into child and adult) of index case, severity of disease, and occurrence of lower respiratory symptoms in index cases were significantly associated with secondary transmission rates in households. Children seem to be equally susceptible to acquire a SARS‐CoV‐2 infection as adults, but they suffer milder courses of the disease or remain asymptomatic.Conclusion: SARS‐CoV‐2 transmission from infected children to other household members occurred rarely in the first wave of the pandemic, despite close physical contact and the lack of hygienic measures.


  • Open Access

    Characterization of the antibody response to SARS‐CoV‐2 in a mildly affected pediatric population

    by Sonja Kopanja, Pia Gattinger, Klara Schmidthaler, Justyna Sieber, Katarzyna Niepodziana, Thomas Schlederer, Lukas Weseslindtner, Karin Stiasny, Florian Götzinger, Winfried F. Pickl, et al.

    Background: While children usually experience a mild course of COVID‐19, and a severe disease is more common in adults, the features, specificities, and functionality of the SARS‐CoV‐2‐specific antibody response in the pediatric population are of interest.Methods: We performed a detailed analysis of IgG antibodies specific for SARS‐CoV‐2‐derived antigens S and RBD by ELISA in 26 SARS‐CoV‐2 seropositive schoolchildren with mild or asymptomatic disease course, and in an equally sized, age‐ and gender‐matched control group. Furthermore, a detailed mapping of IgG reactivity to a panel of microarrayed SARS‐CoV‐2 proteins and S‐derived peptides was performed by microarray technology. The capacity of the antibody response to block RBD‐ACE2 binding and virus neutralization were assessed. Results were compared with those obtained in an adult COVID‐19 convalescent population.Results: After mild COVID‐19, anti‐S and RBD‐specific IgG antibodies were developed by 100% and 84.6% of pediatric subjects, respectively. No difference was observed in regards to symptoms and gender. Mounted antibodies recognized conformational epitopes of the spike protein and were capable to neutralize the virus up to a titer of ≥80 and to inhibit the ACE2‐RBD interaction by up to 65%. SARS‐CoV‐2‐specific IgG responses in children were comparable to mildly affected adult patients.Conclusion: SARS‐CoV‐2 asymptomatic and mildly affected pediatric patients develop a SARS‐CoV‐2‐specific antibody response, which is comparable regarding antigen, epitope recognition, and the ability to inhibit the RBD‐ACE2 interaction to that observed in adult patients after mild COVID‐19.


  • Open Access

    Lessons from low seroprevalence of SARS‐CoV‐2 antibodies in schoolchildren: A cross‐sectional study

    by Zsolt Szépfalusi, Klara Schmidthaler, Justyna Sieber, Sonja Kopanja, Florian Götzinger, Anja Schoof, Jakub Hoz, Birgit Willinger, Athanasios Makristathis, Lukas Weseslindtner, et al.

    Background: Children are discussed as hidden SARS‐CoV‐2 virus reservoir because of predominantly mild or even asymptomatic course of disease. The objective of this cross‐sectional study in May‐July 2020 was to assess the prevalence of SARS‐CoV‐2 antibodies and virus RNA in schoolchildren, consistent with previous infection by contact tracing.Methods: School authorities approached parents for voluntary participation. Interested families were contacted by the study team. A nasal and oropharyngeal swab, a blood sample, and a questionnaire were employed. Primary endpoint was the frequency of SARS‐CoV‐2 real‐time PCR (RT‐PCR) and antibody‐positive children. Antibody positivity was assessed by a highly sensitive first‐line ELISA, and a neutralization assay and two other immunoassays as confirmatory assays.Results: Of 2069 children (median age 13 years, IQR 10‐15), 2 cases (0.1%) tested positive for SARS‐CoV‐2 RNA and 26 cases (1.3%) tested positive for specific antibodies. SARS‐CoV‐2‐specific antibodies exhibited detectable virus‐neutralizing activity in 92% (24 of 26 samples). Seropositivity was associated with a history of mild clinical symptoms in 14 children (53.8%), while 12 children (46.2%) remained asymptomatic. Among 13 seropositive children being tested concomitantly with their siblings, only one pair of siblings was seropositive. Contact tracing revealed adult family members and school teachers as potential index cases.Conclusion: In schoolchildren, the infection rate with SARS‐CoV‐2 is low and associated with a mild or asymptomatic course of disease. Virus spreading seemed to occur more likely in intergenerational contacts than among siblings in the same household. The presence of neutralizing SARS‐CoV‐2 antibodies in children may reflect protective adaptive immunity.